• Extremely American

The Patent Owners of Recombinant Coronavirus: Ralph Baric, Boyd Yount & Kristopher Curtis


[The money and power behind the Coronavirus Patent shown above]


September 22, 2021: It does not take a doctor to understand that Coronavirus patent detail (sourced directly from the USPTO Patent Full Text and Image Database) proves the "gain-of-function" engineering can be traced all the way back to April 20, 2001. These efforts to patent the "mad science" of Corona gain-of-function were well funded and intentional. Through the funding of NIAID (Anthony Fauci), "mad scientists" like Ralph Baric, Kristopher Curtis, and Boyd Yount were encouraged to pursue the nefarious science of gain-of-function and protect their diabolical bio-weapon ideation through the formal US patent process.


Although the full read of the patent is extremely complex, it is imperative to understand the basics of this Coronavirus patent and those behind (it's all captured in official and publicly available documentation). Below, you will find verbatim text pulled from the Coronavirus patent. It is hard to read this information and not be furious with Fauci, Baric, Curtis, Yount, and the bio-science cartel behind what has become the greatest crime against humanity.


Please read and share the information provided below.


By: Extremely American Colin Wright


United States Patent #7,279,327

Curtis , et al.

October 9, 2007 **Please see images for: ( Certificate of Correction ) **

Methods for producing recombinant coronavirus


Abstract


A helper cell for producing an infectious, replication defective, coronavirus (or more generally nidovirus) particle cell comprises (a) a nidovirus permissive cell; (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein; and (c) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon. Compositions for use in making such helper cells, along with viral particles produced from such cells, compositions of such viral particles, and methods of making and using such viral particles, are also disclosed.


Inventors: Curtis; Kristopher M. (Chapel Hill, NC), Yount; Boyd (Hillsborough, NC), Baric; Ralph S. (Haw River, NC)Assignee:The University of North Carolina at Chapel Hill (Chapel Hill, NC)


Family ID:26963129 Appl. No.:10/474,962

Filed:April 19, 2002PCT

Filed:April 19, 2002PCT No.:PCT/US02/12453371(c)(1),(2),(4)

Date:May 25, 2004PCT Pub. No.:WO02/086068PCT Pub.

Date:October 31, 2002

Prior Publication Data Document Identifier

Publication Date US 20040235132 A1Nov 25, 2004

Related U.S. Patent Documents Application Number Filing Date Patent Number

Issue Date 60285320Apr 20, 200160285318 Apr 20, 2001


SUMMARY OF THE INVENTION


A first aspect of the present invention is a helper cell for producing an infectious, replication defective, nidovirus particle. The helper cell comprises (a) a nidovirus permissive cell (e.g., a cell permissive of replication but not necessarily infection); (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein (e.g., lacks one, two, three, four or all); and (c) at least one separate helper RNA (e.g., one, two, three, four, etc. separate helper RNAs) encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon.


Example nidoviruses that may be used to carry out the present invention include members of the familes Coronaviridae and Arteriviridae. Currently preferred are the coronaviruses.


In some embodiments, the replicon RNA further comprises a sequence encoding at least one of the nidovirus structural proteins (for example, the M, N, and/or S genes). In other embodiments, the replicon RNA lacks all of the nidovirus structural proteins. Thus in some embodiments, the helper RNA contains (or helper RNAs contain) at least one gene encoding a structural protein, such as the E, M, N, and/or S genes.


In certain preferred embodiments, the replicon RNA and/or the helper RNA contains at least one attenuating gene order rearrangement among the 3A, 3B, HP, S, E, M and N genes.


In certain embodiments, the helper RNA and/or the replicon RNA may include a promoter (in the helper RNA, to drive expression of the appropriate helper gene or genes; in the replicon RNA, to drive expression of the coronavirus genes or the heterologous genes (which may be driven by the same or a different promoter). In certain embodiments of the invention, the helper cell may include a heterologous DNA encoding the replicon RNA, and/or a heterologous DNA encoding the helper RNA, with the replicon RNA and/or the helper RNA being transcribed from the corresponding DNA in the permissive cell.


A further aspect of the present invention is a method of making infectious, replication defective, nidovirus particles, comprising: providing a helper cell as described above, producing the nidovirus particles in the helper cell; and then collecting the nidovirus particles from the helper cell. The replicon RNA and the at least one separate helper RNA are stably or transiently introduced into the helper cell by any suitable means, such as electroporation of the RNA into the cell, introduction of DNA into the cell as noted above, etc.


A still further aspect of the invention is infectious nidovirus particles containing a heterologous RNA within a replicon RNA as described above. Such particles may be produced by the methods described above. In certain preferred embodiments the present invention provides a composition comprising a population of infectious, replication defective, nidovirus particles, wherein each particle comprises a nidovirus replicon RNA, wherein the replicon RNA comprises a nidovirus packaging signal and one or more heterologous RNA sequences, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein, and wherein the population contains no detectable replication-competent nidovirus particles as determined by passage on nidovirus permissive cells (e.g., cells permissive of infection and replication) in culture. As previously, the replicon RNA may further comprise a sequence encoding at least one nidovirus structural protein. Also as previously, the replicon RNA may contain at least one attenuating gene order rearrangement among the 3a, 3b, Hp, S, E, M and N genes.


A still further aspect of the present invention is a pharmaceutical formulation comprising infectious nidovirus particles as described above in a pharmaceutically acceptable carrier.


A still further aspect of the present invention is a method of introducing a heterologous RNA into a subject, comprising administering infectious nidovirus particles as described herein to the subject in an amount effective to introduce the heterologous RNA into the subject.


Nidovirus replicon RNAs and helper RNAs as described above, independent of the helper cell, are also an aspect of the present invention. Such RNAs may be provided in a suitable carrier such as an aqueous carrier for introduction into the helper cell as described above.


Further aspects of the present invention include DNAs encoding replicon RNAs or helper RNAs as described above, along with vectors and recombinant constructs carrying or comprising such DNA, all of which may be used to create the helper cells described above, and which may be provided in a suitable carrier such as an aqueous carrier for introduction into a helper cell as described above.


Full Coronavirus Patent Link: Methods for producing recombinant coronavirus